#United States #Reston #Chief Financial Officer #Decera Clinical #Frank J. Garafalo

Decera Clinical Accelerates Growth with CFO Appointment

Decera Clinical, a leader in Scientific Activation™, has officially announced the addition of Frank J. Garafalo as their new Chief Financial Officer (CFO). This strategic move is expected to enhance the company's capacity to push forward its ambitious 2026 mission, aimed at driving long-term value through robust revenue streams, high margins, and clear operational frameworks.

Garafalo brings a wealth of experience in constructing and managing high-performing organizations. His history of translating intricate strategies into effective financial operations is well regarded in the industry. As the demand for scientific evidence intensifies in the healthcare space, Garafalo's appointment comes at a critical juncture for Decera Clinical, perfectly aligning with the company’s goals of delivering actionable insights and ensuring clarity amidst data saturation.

In a statement about the appointment, Leo Tarkovsky, CEO of Decera Clinical, emphasized, "Frank's arrival marks a significant milestone in our 2026 roadmap. As a company dedicated to decoding complex science and mobilizing evidence into action, we need leaders who bring both strategic rigor and operational clarity. We're confident in Frank's ability to lead us through a transformative phase of growth and operational excellence."

Garafalo previously served as CFO at Eden Capital, a private equity firm, where he played a pivotal role in managing financial strategies for portfolio companies. He was also Senior Vice President of Finance at WCG Clinical, where he contributed to significant revenue growth and operational scaling, effectively maneuvering through increasingly complex offerings. His career includes vital financial roles at Schoology Inc. and Certara, where he was instrumental in facilitating turnarounds and steering successful exit strategies.

Expressing his enthusiasm about the new role, Garafalo stated, "Decera Clinical possesses a remarkable chance to establish a world-class financial platform that aligns with its forward-thinking vision. I'm thrilled to collaborate with the leadership team to bolster our infrastructure, enhance performance metrics, and amplify enterprise value as we navigate this high-growth period."

The infusion of Garafalo's talent is expected to bolster Decera Clinical's aspirations as it continues to evolve its mission of Scientific Activation™. The company operates three key segments: Decera Clinical Education, Decera Clinical Insights, and Decera Clinical Communications. Together, these divisions work to provide healthcare professionals and life sciences organizations with comprehensive accredited continuing education, real-world insights, and strategic communication services.

By merging deep scientific knowledge with extensive healthcare professional intelligence, Decera Clinical aims to eliminate barriers to access and expedite the adoption of groundbreaking therapies, thereby benefiting patients and healthcare systems alike.

With Garafalo at the helm of financial strategies, Decera Clinical is poised to ensure evidence is not only accessible but actionable, thus maintaining credibility and significant impact at an organizational scale. As clinical evidence continues to grow in complexity, Garafalo's leadership will be integral in sustaining the company’s operational integrity and financial discipline while remaining committed to innovation and rapid execution.

In summary, the appointment of Frank J. Garafalo marks a significant development in Decera Clinical's strategic growth, reinforcing their operations with leadership that is committed to optimizing performance and maximizing value in the face of evolving market demands.